User:MarkZusab/drafts/iml

Ira M. Leviton (born 1959) is a physician and professor specializing in infectious diseases, based in Bronx, New York.

Early life and education
Leviton was born in Brooklyn, New York on July, 22 1959. He graduated from the Albert Einstein College of Medicine at Yeshiva University in 1984 with a Doctor of Medicine. He completed his his education at the Albert Einstein College of Medicine, his residency at Montefiore Medical Center, and his fellowship at Jacobi Medical Center.

Career and research
Leviton is currently an Associate Professor and the director of the Division of Infectious Diseases at the Albert Einstein College of Medicine. He also works for Montefiore Medical Center. Leviton is certified in both Infectious Disease and Internal Medicine by the American Board of Internal Medicine. He first earned his NY State Medical License in 1985 and it is active through 2020. Leviton is also the co-chairman of the Biomedical Research Alliance of New York Institutional Review Board.

According to ProPublica, Leviton was reimbursed, on average, $189 per patient with a total of $37,200 paid by Medicare in 2015. Leviton was also paid at least $1,610 by the pharmaceutical industry in 2013–2014, with $1,582 coming from Cubist Pharmaceuticals.

Throughout his career, Leviton has published numerous papers, garnering many citations in the field. His papers have been published by journals including the Journal of the American Medical Association, Clinical Infectious Diseases, Current Pharmaceutical Design, Cancer Investigation, Reviews of Infectious Diseases, Antimicrobial Agents and Chemotherapy, Journal of Bacteriology, and The American Journal of Medicine.

Selected publications

 * In-training examination in infectious diseases and certification examinations. Leviton, I., 2015, Clinical Infectious Diseases. 60, 5, p. 684-685 2 p.
 * Commentary on "the impact of anti-infective drug shortages on hospitals in the United States: Trends and causes". Leviton, I., Mar 1 2012, Clinical Infectious Diseases. 54, 5, p. 692-693 2 p.
 * Antibiotic guidelines for community-acquired pneumonia: Are they effective and do physicians comply?. Amodio-Groton, M., Sinnett, M. J., Culshaw, D. & Leviton, I., Aug 1 2003, Drug Benefit Trends. 15, 8, p. 40-46 7 p.
 * Registering Clinical Trials [5] (multiple letters). Leviton, I., Della Cioppa, G., Garaud, J. J., Dickersin, K. & Rennie, D., Nov 19 2003, Journal of the American Medical Association. 290, 19, p. 2545-2546 2 p.
 * Separating fact from fiction: The data behind allergies and side effects caused by penicillins, cephalosporins, and carbapenem antibiotics. Leviton, I., 2003, Current Pharmaceutical Design. 9, 12, p. 983-988 6 p.
 * Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: A randomized, double-blind, multicenter study. Rubinstein, E., Cammarata, S. K., Oliphant, T. H., Wunderink, R. G., Labrooy, J., Moran, J. L., Richards, B., Grimard, D., Landis, S. J., Rotstein, C., Chavez, E., Northland, R., Triantafilo, V., Vasquez, P., Kolek, V., Kucera, M., Reiterer, P., Weidenhoffer, I., Andrews, C., McLaren, I. & 78 others, 2001, Clinical Infectious Diseases. 32, 3, p. 402-412 11 p.
 * Inhibitors of protein synthesis. Leviton, I., 1999, Cancer Investigation. 17, 1, p. 87-92 6 p.
 * General principles of antibiotic therap.y Leviton, I., 1998, Cancer Investigation. 16, 5, p. 345-349 5 p.
 * Randomized trial of itraconazole oral solution for oropharyngeal candidiasis in HIV/AIDS patients. Graybill, J. R., Vazquez, J., Darouiche, R. O., Morhart, R., Greenspan, D., Tuazon, C., Wheat, L. J., Carey, J., Leviton, I., Hewitt, R. G., MacGregor, R. R., Valenti, W., Restrepo, M. & Moskovitz, B. L., Jan 1998, The American Journal of Medicine. 104, 1, p. 33-39 7 p.
 * In vitro activities of ciprofloxacin and rifampin alone and in combination against growing and nongrowing strains of methicillin-susceptible and methicillin-resistant Staphylococcus aureus. Bahl, D., Miller, D. A., Leviton, I., Gialanella, P., Wolin, M. J., Liu, W., Perkins, R. & Miller, M. H., Jun 1997, Antimicrobial Agents and Chemotherapy. 41, 6, p. 1293-1297 5 p.
 * Tobramycin uptake in Escherichia coli membrane vesicles. Leviton, I., Fraimow, H. S., Carrasco, N., Dougherty, T. J. & Miller, M. H., 1995, Antimicrobial Agents and Chemotherapy. 39, 2, p. 467-475 9 p.
 * Criteria for use of intravenous ciprofloxacin for infections in adult patients. Frisolone, J., Manzo, J. & Leviton, I., 1993, Clinical Pharmacy. 12, 3, p. 226-232 7 p.
 * Tobramycin uptake in Escherichia coli is driven by either electrical potential or ATP. Fraimow, H. S., Greenman, J. B., Leviton, I., Dougherty, T. J. & Miller, M. H., 1991, Journal of Bacteriology. 173, 9, p. 2800-2808 9 p.
 * Fungal peritonitis in patients receiving peritoneal dialysis: experience with 11 patients and review of the literature. Eisenberg, E. S., Leviton, I. & Soeiro, R., May 1986, Reviews of Infectious Diseases. 8, 3, p. 309-321 13 p.